BIIB Apr 2023 230.000 call
| Previous close | 42.50 |
| Open | 42.50 |
| Bid | 31.90 |
| Ask | 37.60 |
| Strike | 230.00 |
| Expiry date | 2023-04-21 |
| Day's range | 42.50 - 42.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 15 |
- GlobeNewswire
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United StatesCAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidenc
- Zacks
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.
- Motley Fool
Should You Buy Biogen Before a Big July Decision?
Over time, Biogen (NASDAQ: BIIB) created a true success story. Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market. Now, though, Biogen may have found that new growth source.
